These results show only some tendencies (the statistical significance depends on the tests used) but suggest that ER-positive breast tumors with low HSF1 expression may be more sensitive to treatment with 4-OHT and palbociclib than cases with high HSF1 levels. The gene discussed is HSF1; the disease is breast neoplasm.